0
0
Home » Pharmaceuticals » Therapy Area » Women's Health

Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility – Drugs In Development, 2022, provides an overview of the Women Infertility (Women's Health) pipeline landscape.

Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 26, 11, 1, 2, 28, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 4 molecules, respectively.

Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).

– The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

AlphaMab Co Ltd

Amega Biotech

Anelleo Inc

Aprilbio Co Ltd

Aptorum Group Ltd

ASKA Pharmaceutical Holdings Co Ltd

Bayer AG

BCI Pharma SA

Beijing FuKangren Bio-pharm Tech Co Ltd

Beijing SL Pharmaceutical Co Ltd

Bharat Serums And Vaccines Ltd

Bol Pharma

Bopin (Shanghai) Biomedical Technology Co Ltd

Chugai Pharmaceutical Co Ltd

Context Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Egret Therapeutics Inc

Eikonoklastes Therapeutics Inc

ElexoPharm GmbH

Endomet Biosciences Inc

Enteris BioPharma Inc

Eurofarma Laboratorios SA

Evestra Inc

Evotec SE

Ferring International Center SA

Ferring Pharmaceuticals Inc

Forendo Pharma Ltd

GeneScience Pharmaceuticals Co Ltd

Genome & Co

Glycotope GmbH

Hangzhou Metai Pharmaceutical Technology Co Ltd

Hope Medicine Inc

Igenomix SL

Igyxos SA

Immunitor Inc

Insud Pharma

Ironwood Pharmaceuticals Inc

Isifer AB

Jiangsu Hengrui Medicine Co Ltd

Kissei Pharmaceutical Co Ltd

Livzon Pharmaceutical Group Co Ltd

Luye Pharma Group Ltd

Medibiofarma SL

Mithra Pharmaceuticals SA

Mitsubishi Tanabe Pharma Corp

Myovant Sciences Ltd

Navad Life Sciences Pte Ltd

Neuromagen Pharma Ltd

Nippon Shinyaku Co Ltd

NutriBand Inc

ObsEva SA

Oxolife SL

Pangen Biotech Inc

Park of Active Molecules

Pharmasyntez

Predictive Therapeutics LLC

PregLem SA

Reven Holdings Inc

Shandong TheraWisdom Biopharma Co Ltd

Shanghai Jing Ze Biotechnology Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Suzhou JiSheng Pharmaceutical Co Ltd

SYNG Pharmaceuticals Inc

Synokem Pharmaceuticals Ltd

Takeda Pharmaceutical Co Ltd

Temple Therapeutics BV

TiumBio Co Ltd

Trophogen Inc

Unicohealth Pharma Co Ltd

ValiRx Plc

Viramal Ltd

Xbrane Biopharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Women Infertility – Overview

Women Infertility – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Women Infertility – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Women Infertility – Companies Involved in Therapeutics Development

Women Infertility – Drug Profiles

Women Infertility – Dormant Projects

Women Infertility – Discontinued Products

Women Infertility – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Women Infertility, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Women Infertility – Dormant Projects, 2022

Women Infertility – Dormant Projects, 2022 (Contd..1)

Women Infertility – Dormant Projects, 2022 (Contd..2)

Women Infertility – Dormant Projects, 2022 (Contd..3)

Women Infertility – Dormant Projects, 2022 (Contd..4)

Women Infertility – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Women Infertility, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports